These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 27378345)
1. Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab. Bjoern J; Iversen TZ; Nitschke NJ; Andersen MH; Svane IM Cytotherapy; 2016 Aug; 18(8):1043-1055. PubMed ID: 27378345 [TBL] [Abstract][Full Text] [Related]
2. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer. Iversen TZ Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457 [TBL] [Abstract][Full Text] [Related]
3. Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial. Aamdal E; Inderberg EM; Ellingsen EB; Rasch W; Brunsvig PF; Aamdal S; Heintz KM; Vodák D; Nakken S; Hovig E; Nyakas M; Guren TK; Gaudernack G Front Immunol; 2021; 12():663865. PubMed ID: 34046035 [TBL] [Abstract][Full Text] [Related]
4. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. Yuan J; Ginsberg B; Page D; Li Y; Rasalan T; Gallardo HF; Xu Y; Adams S; Bhardwaj N; Busam K; Old LJ; Allison JP; Jungbluth A; Wolchok JD Cancer Immunol Immunother; 2011 Aug; 60(8):1137-46. PubMed ID: 21465316 [TBL] [Abstract][Full Text] [Related]
5. TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma. De Keersmaecker B; Claerhout S; Carrasco J; Bar I; Corthals J; Wilgenhof S; Neyns B; Thielemans K J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114500 [TBL] [Abstract][Full Text] [Related]
6. A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma. Kjeldsen JW; Lorentzen CL; Martinenaite E; Ellebaek E; Donia M; Holmstroem RB; Klausen TW; Madsen CO; Ahmed SM; Weis-Banke SE; Holmström MO; Hendel HW; Ehrnrooth E; Zocca MB; Pedersen AW; Andersen MH; Svane IM Nat Med; 2021 Dec; 27(12):2212-2223. PubMed ID: 34887574 [TBL] [Abstract][Full Text] [Related]
7. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. Weber JS; Kudchadkar RR; Yu B; Gallenstein D; Horak CE; Inzunza HD; Zhao X; Martinez AJ; Wang W; Gibney G; Kroeger J; Eysmans C; Sarnaik AA; Chen YA J Clin Oncol; 2013 Dec; 31(34):4311-8. PubMed ID: 24145345 [TBL] [Abstract][Full Text] [Related]
8. Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study-A Brief Research Report. Kjeldsen JW; Iversen TZ; Engell-Noerregaard L; Mellemgaard A; Andersen MH; Svane IM Front Immunol; 2018; 9():2145. PubMed ID: 30283461 [No Abstract] [Full Text] [Related]
9. Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Sarnaik AA; Yu B; Yu D; Morelli D; Hall M; Bogle D; Yan L; Targan S; Solomon J; Nichol G; Yellin M; Weber JS Clin Cancer Res; 2011 Feb; 17(4):896-906. PubMed ID: 21106722 [TBL] [Abstract][Full Text] [Related]
10. Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. Iversen TZ; Engell-Noerregaard L; Ellebaek E; Andersen R; Larsen SK; Bjoern J; Zeyher C; Gouttefangeas C; Thomsen BM; Holm B; Thor Straten P; Mellemgaard A; Andersen MH; Svane IM Clin Cancer Res; 2014 Jan; 20(1):221-32. PubMed ID: 24218513 [TBL] [Abstract][Full Text] [Related]
11. Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Da Gama Duarte J; Parakh S; Andrews MC; Woods K; Pasam A; Tutuka C; Ostrouska S; Blackburn JM; Behren A; Cebon J Front Immunol; 2018; 9():411. PubMed ID: 29552014 [TBL] [Abstract][Full Text] [Related]
12. Increased indoleamine 2,3-dioxygenase activity and expression in prostate cancer following targeted immunotherapy. Zahm CD; Johnson LE; McNeel DG Cancer Immunol Immunother; 2019 Oct; 68(10):1661-1669. PubMed ID: 31606777 [TBL] [Abstract][Full Text] [Related]
13. From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past. Shadbad MA; Hajiasgharzadeh K; Derakhshani A; Silvestris N; Baghbanzadeh A; Racanelli V; Baradaran B Front Immunol; 2021; 12():623639. PubMed ID: 33692796 [TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for malignant melanoma. Zeiser R; Schnitzler M; Andrlova H; Hellige T; Meiss F Curr Stem Cell Res Ther; 2012 May; 7(3):217-28. PubMed ID: 22329580 [TBL] [Abstract][Full Text] [Related]
15. Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study. Weide B; Martens A; Wistuba-Hamprecht K; Zelba H; Maier L; Lipp HP; Klumpp BD; Soffel D; Eigentler TK; Garbe C Cancer Immunol Immunother; 2017 Apr; 66(4):441-449. PubMed ID: 28008452 [TBL] [Abstract][Full Text] [Related]
16. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. Belli F; Testori A; Rivoltini L; Maio M; Andreola G; Sertoli MR; Gallino G; Piris A; Cattelan A; Lazzari I; Carrabba M; Scita G; Santantonio C; Pilla L; Tragni G; Lombardo C; Arienti F; Marchianò A; Queirolo P; Bertolini F; Cova A; Lamaj E; Ascani L; Camerini R; Corsi M; Cascinelli N; Lewis JJ; Srivastava P; Parmiani G J Clin Oncol; 2002 Oct; 20(20):4169-80. PubMed ID: 12377960 [TBL] [Abstract][Full Text] [Related]
17. Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study. Dalle S; Mortier L; Corrie P; Lotem M; Board R; Arance AM; Meiss F; Terheyden P; Gutzmer R; Buysse B; Oh K; Brokaw J; Le TK; Mathias SD; Scotto J; Lord-Bessen J; Moshyk A; Kotapati S; Middleton MR BMC Cancer; 2021 May; 21(1):642. PubMed ID: 34051732 [TBL] [Abstract][Full Text] [Related]
18. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses. Wei Y; Sticca RP; Holmes LM; Burgin KE; Li J; Williamson J; Evans L; Smith SJ; Stephenson JJ; Wagner TE Int J Oncol; 2006 Mar; 28(3):585-93. PubMed ID: 16465362 [TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study. Schreiber S; Kämpgen E; Wagner E; Pirkhammer D; Trcka J; Korschan H; Lindemann A; Dorffner R; Kittler H; Kasteliz F; Küpcü Z; Sinski A; Zatloukal K; Buschle M; Schmidt W; Birnstiel M; Kempe RE; Voigt T; Weber HA; Pehamberger H; Mertelsmann R; Bröcker EB; Wolff K; Stingl G Hum Gene Ther; 1999 Apr; 10(6):983-93. PubMed ID: 10223732 [TBL] [Abstract][Full Text] [Related]
20. Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma. Wilgenhof S; Corthals J; Heirman C; van Baren N; Lucas S; Kvistborg P; Thielemans K; Neyns B J Clin Oncol; 2016 Apr; 34(12):1330-8. PubMed ID: 26926680 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]